ARTICLE | Clinical News

Tomtovok afatinib: Additional Phase II data

October 25, 2010 7:00 AM UTC

Additional data from the open-label, single-arm, U.S. and Taiwanese Phase II LUX-Lung 2 trial in 129 patients showed that afatinib as first- or second-line therapy led to OS and PFS of 24 and 14 month...